US alleges Novartis paid kickbacks to specialty pharmacies
In a new lawsuit, the U.S. government alleges Novartis paid kickbacks to specialty pharmacies to increase sales of deferasirox (Exjade), which removes excess iron from the blood of patients who receive transfusions, and mycophenolic acid (Myfortic), to prevent rejection of kidney transplants.
In a new lawsuit, the US government alleges Novartis paid kickbacks to specialty pharmacies to increase sales of deferasirox (Exjade), which removes excess iron from the blood of patients who receive transfusions, and mycophenolic acid (Myfortic), to prevent rejection of kidney transplants.
Related: 7 strategies for managing the rise in specialty drugs costs
In the suit, filed in US District Court in Manhattan, the United States is seeking as much as $3.3 billion in damages. A group of specialty pharmacies submitted thousands of fraudulent reimbursement claims to Medicare and Medicaid for the 2 drugs, according to the lawsuit, Bloombergreported. Novartis paid kickbacks in the form of rebates, so the pharmacies would recommend the drugs to patients and boost sales, according to the suit.
Related:Specialty drug coverage varies across health plans
Novartis said it provided legitimate rebates to the pharmacies in the court filing. The company “continues to dispute the allegations and is continuing to defend itself in this litigation,” Novartis said in a statement to Bloomberg. “We look forward to a full presentation of all of the evidence during the trial.”
Read next: High healthcare costs driven by spike in Rx costs
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More
